Cancer lettersFeb 14, 2026

mRNA COVID-19 Vaccines May Increase Tumor Response to Immune Checkpoint Therapy in 4,407 Patients

mRNA Technology Weekly Brief ↗PubMed ↗DOI ↗

Updated Feb 15, 2026

Abstract

SARS-CoV-2 mRNA vaccination within 100 days of starting immune checkpoint inhibitor therapy is associated with improved overall survival in patients with non-small cell lung cancer and malignant melanoma.

COVID-19 mRNA vaccination near the initiation of immune checkpoint inhibitor therapy may correlate with better patient outcomes.
Findings were validated in a larger, independent real-world cohort from Clalit Health Services.
The analysis aimed to replicate earlier observations regarding the relationship between vaccination and survival rates.

Simplified

A recent studyhas demonstrated that SARS-CoV-2 mRNA vaccination within 100 days of initiating immune checkpoint inhibitor (ICI) therapy is associated with improved overall survival (OS) in patients with non-small cell lung cancer (NSCLC) and malignant melanoma. We sought to validate these findings in an independent and larger real-world cohort. Using clinical and survival data from the Clalit Health Services, we reproduced the primary analyses of Grippin et al. and confirmed that COVID-19 mRNA vaccination near the time of ICI initiation correlates with improved patient outcomes. 1

Full Text

Full text is available at the source.

View Full Text ↗

Funding

Competing interests

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this manuscript.

PubMed

mRNA COVID-19 Vaccines May Increase Tumor Response to Immune Checkpoint Therapy in 4,407 Patients

Abstract

Full Text

Funding

Competing interests

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the mrna technology brief